ARA-290 is a tissue-protective, erythropoietin-derived research peptide studied for its anti-inflammatory, neuroprotective, and endothelial-supportive properties. It selectively activates innate repair pathways without stimulating red blood cell production.
$76.00
For laboratory research use only. Not for human or animal use or consumption. Not a drug, food, dietary supplement, or cosmetic. Not approved by the FDA for any medical use.
ARA-290 is an 8-amino-acid peptide derived from the B-helix region of erythropoietin (EPO), engineered to retain EPO’s tissue-protective benefits while eliminating its erythropoietic activity. It functions as an Innate Repair Receptor (IRR) agonist, selectively activating a heterodimeric receptor composed of EPOR and CD131.
Through IRR activation, ARA-290 initiates anti-inflammatory, anti-apoptotic, and neuroprotective signaling pathways. This mechanism supports modulation of immune overactivation, protection of endothelial cells, and promotion of small-fiber nerve regeneration. As a result, ARA-290 is frequently studied in research settings involving neuropathy, ischemic injury, and microvascular dysfunction.
Subcutaneous Administration
General Dose: 2 mg per day
Administration Frequency: Once daily
Treatment Duration: Commonly administered for 28 days, followed by a monitoring period without treatment to assess lasting effects
Intravenous Administration
General Dose: 2 mg per dose
Administration Frequency: Three times weekly
Treatment Duration: Typically over a 4-week period
Important Notes
Dosage may vary depending on the specific condition being studied, including applications such as sarcoidosis-associated neuropathic pain or diabetic neuropathy. Protocol adjustments may be made based on research objectives and observed outcomes.
Reviews
There are no reviews yet.